YL201 for Injection

DRUG2 trials

Sponsors

MediLink Therapeutics (Suzhou) Co., Ltd.

Conditions

Advanced Solid TumorMetastatic Castration-resistant Prostate Cancer (mCRPC)

Phase 1

A Study YL201 in Patients With Selected Advanced Solid Tumors

Active, not recruitingNCT06057922

MediLink Therapeutics (Suzhou) Co., Ltd.Advanced Solid Tumor

Start: 2023-09-22End: 2028-10-01Target: 990Updated: 2026-03-12

Phase 2

A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC

RecruitingNCT06241846

MediLink Therapeutics (Suzhou) Co., Ltd.Metastatic Castration-resistant Prostate Cancer (mCRPC)

Start: 2024-02-22End: 2029-02-28Target: 100Updated: 2025-08-27

Related Papers

Associations of Baseline Neutrophil-to-Lymphocyte Ratio with Efficacy and Toxicity of the B7H3 ADC YL201, Linked to Interleukin-6: Analysis of the Phase 1/1b Trial

Clinical Cancer Research2026-09-09

Phase 1/2 study of YL201, an anti-B7H3 antibody–drug conjugate (ADC), in patients with relapsed or refractory (R/R) Ewing sarcoma and chondrosarcoma.

Journal of Clinical Oncology2026-05-27

Phase 1/2 study of YL201, an anti-B7H3 antibody–drug conjugate (ADC), in patients with previously treated advanced pancreatic ductal adenocarcinoma (PDAC).

Journal of Clinical Oncology2026-05-27

Phase 2 study of YL201, an anti-B7H3 antibody–drug conjugate (ADC), in heavily pretreated metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology2026-05-27

A B7H3-targeting antibody–drug conjugate in advanced solid tumors: a phase 1/1b trial

Nature Medicine2025-03-1336 citations